York Chairman David B. Jones, MD
|
|
- Barrie Weaver
- 6 years ago
- Views:
Transcription
1 York Chairman David B. Jones, MD Pathologists Abby W. Davis, MD David A. Derrick, MD J. Ander Pindzola, MD John A. Wright, MD Stanley D. Hurtt, MD Matthew F. Georgy, MD Michelle L. Erickson, MD, MBA William M. Taylor, MD Pathologists' Assistants Mandi L. Howell, MS Janine A. Riben, MHS Fred J. Faust, Sr., MS Jennifer L. Fuhrman, MS Clinical Chemist Stephen M. Manzella, PhD. Editor Clinical Microbiologist Arthur E. Crist, Jr., PhD Administrative Director Martin L. Beaverson, MT Operations Manager Tina M. Stover, MT Gettysburg Pathologist Angela Brooks, MD Administrative Director David W. Meeder, MT, MBA THERAPEUTIC PHLEBOTOMY CHANGE Julie Hicks, Supervisor, Blood Resources Therapeutic phlebotomy (the removal 500 ml of blood) is typically an outpatient procedure performed by Blood Resources at Apple Hill Medical Center for the treatment of: polycythemia, hemochromatosis, porphyria cutanea tarda, erythrocytosis or myeloproliferative disease. One of the WellSpan York Hospital Laboratory regulatory agencies now requires the Blood Bank Medical Director (or her designee) to review and approve: the indications for a therapeutic phlebotomy, the therapeutic goal of the phlebotomy, the treatment plan and the patient s record prior to the therapeutic phlebotomy. Because of this change and the time needed to perform this review, Blood Resources is requesting all ordering physicians offices to fax the order for therapeutic phlebotomy to Blood Resources prior to or at the time of scheduling the patient for the procedure. Blood Resources has revised and is distributing a new therapeutic phlebotomy order form to all physicians who currently order therapeutic phlebotomies. The new form is completed by filling in the blanks or checking the appropriate boxes for the required information. This new form and the new review process is effective 11/1/11. Please be sure to inform this issue Therapeutic Phlebotomy Change P. 1 My Patient Has An Antibody? Now What? P. 2 Herpes Simplex Type 1 & 2 Detection & Typing P Antibiograms P. 4 Laboratory Services Bulletin [March 2012, Vol. 42. No. 1] 1
2 any affected office staff of the change. This is a substantial change for all those involved in ordering and performing therapeutic phlebotomies and Blood Resources wishes to thank you for your cooperation and patience in making this transition. If there are any questions regarding this change, please call (717) Physicians using WellSpan Gettysburg Hospital for therapeutic phlebotomies should contact Margaret Nicastro, Outpatient (717) MY PATIENT HAS AN ANTIBODY? NOW WHAT? Barbara Steiber, MT (ASCP), Clinical Instructor-Immunohematology For the clinician, the notification from the Transfusion Service that one s patient has an alloantibody means one thing: there is going to be a delay in providing red blood cell products for that patient. The good news is that this problem will not, in most cases, delay the transfusion of other blood components such as platelets, plasma and cryoprecipitate. The bad news, and this is critical to understand, is that in these cases O negative red blood cells are NOT the universal donor and may NOT be safe to transfuse until the problem has been resolved. This often raises the question of how or why did the patient make the antibody and is this preventable? Patients may make antibodies to red blood cell antigens following exposure to foreign RBC antigens via transfusion, pregnancy or even sharing needles when injecting IV drugs; however, some antibodies can be made with no documented exposure. Patients can make antibodies to their own red blood cells as in autoimmune hemolytic anemia. Some medications can cause a patient to exhibit apparent antibodies to red blood cells. In this discussion, only alloantibodies will be addressed. The percentage of patients who have antibodies varies with the category of patient that the clinician encounters. A population of chronically transfused patients will have a higher probability than an acutely transfused patient population simply because the former are exposed repeatedly over time. For example, oncology and sickle cell patients are much more likely to present with antibodies than a trauma patient. Is the formation of alloantibodies preventable? In most cases, it is not. It would be cost prohibitive and extremely time consuming to provide phenotypically matched red blood cells to all patients. This is only done for selected patient populations such as those with sickle cell disease. For the transfusion service Clinical Laboratory Scientist, the detection of one or multiple alloantibodies in a patient s plasma indicates that more time, testing and resources will be required to supply a product that is safe to transfuse. The presence of alloantibody is first suspected when evaluating the results of the antibody screen. This a qualitative test performed on all pretransfusion specimens. If the screening test is negative, it is generally safe to select ABO/Rh compatible red cell units for transfusion (see chart). Acceptable ABO/Rh options when no antibodies are present. Laboratory Services Bulletin [March 2012, Vol. 42. No. 1] 2
3 If the screening test is positive, it alerts the scientist that one or more antibodies are present. The next step is to identify the specificity of the antibody or antibodies so that antigen negative, compatible red blood cells may be selected and crossmatched for the patient. The process of antibody identification is not a standardized test where one size fits all. Each patient s problem is unique and many variables are involved which will determine how easy or difficult it will be to solve the puzzle. Is the antibody new onset or has the patient exhibited this previously? Is there a single antibody or multiple antibodies? What is the frequency of distribution of the corresponding antigens in the population of donors? Which tests and techniques must be employed to discern the answer to the mystery? How much time and what reagents are needed? What is the probability that the necessary units will be found in the current inventory? Will units have to be obtained from the rare donor population and imported to our facility? These variables can result in a solution that requires a simple, straightforward workup taking an hour or two, or one that requires several hours or even days to solve. Fortunately, the latter is the exception, not the rule. If the antibody is a previously identified problem, obviously the delay will be shorter than if a new antibody is detected. If a patient has a positive antibody screen, a footnote will be added to alert the clinician that there will be a delay in providing red blood cells. Another point to remember is that the presence of a single antibody does not equate to having blood available more quickly than the presence of multiple antibodies. The patient with multiple antibodies may require a lengthy and more extensive identification process, but if the corresponding antigens are lower in frequency, it will be easier to find compatible units. An example would be the presence of anti-kell and anti- E. The patient has two antibodies but approximately 65-70% of the Rh positive and 90% of the Rh negative population will be compatible. Therefore, the delay in transfusion will be minimal. Conversely, for a patient with a single antibody to a very high frequency antigen, it will be more difficult to find compatible units. An example of this scenario would be a patient with anti-k (Cellano). There is only one antibody but 99+% of the population carries that antigen on their red blood cells and units would have to be obtained from the rare donor supply, probably frozen units that would require extra processing before they are ready to transfuse. At the Wellspan Transfusion Services, a dedicated and experienced staff of pathologists and clinical laboratory scientists work together with the clinicians and nursing staff to provide safe, compatible blood products for all who require transfusion therapy. We welcome questions and provide consultation to any staff members or their patients who have concerns regarding transfusion related issues. Please call us anytime with questions at the York Hospital Blood Bank, , or the Gettysburg Hospital Blood Bank, Herpes Simplex Type 1 and 2 Detection and Typing: Molecular Testing to Replace Tissue Culture Isolation and Identification Arthur E. Crist, Jr., Ph.D., Director, Clinical and Molecular Microbiology TEST NAME: Herpes Simplex Virus Detection and Typing TEST CODE: HSV PCR CPT-4 CODE: X 2 SPECIMEN: Specimens collected and transported using the BD Universal Viral Transport Kit (Contains one flocked swab and one red top 3 ml UVT tube) REFERENCE RANGE: Negative for Herpes simplex virus by DNA Amplification EFFECTIVE DATE: April 2, 2012 CONTACTS: Microbiology Lab ; Dr. Crist ; Dave Bankert LAB WEBSITE: Beginning April 2, 2012, the Microbiology Laboratory at York Hospital will be moving from a tissue culture based to a molecular based assay for detection and typing of herpes simplex virus. A study using the Laboratory Services Bulletin [March 2012, Vol. 42. No. 1] 3
4 molecular based method was conducted as follows in order to verify assay performance. The BD ProbeTec TM HSV Q x Amplified DNA Assay for detection and typing of herpes simplex virus (BD-HSV) performed on the BD Viper TM Instrument was compared to the shell vial tissue culture method used in our laboratory. The shell vial tissue culture consisted of inoculating each specimen to two vials; one containing mink lung cells (Mv1Lu) and the other containing MRC5 cells (Diagnostic Hybrids). Shell vial cultures were incubated at 37 o C for up to 5 days and inspected daily for cytopathic effect (CPE). All CPE positive samples were then typed using fluorescein-tagged monoclonal antibodies to HSV-1 or HSV-2 (Diagnostic Hybrids). There were 323 specimens evaluated in this study. BD-HSV produced 128 positive results compared to 117 by our shell vial culture. Of the 116 specimens that were positive by both methods, there were no discrepant typing results (55 HSV-1 and 61 HSV-2). When compared to shell vial culture, the BD-HSV had sensitivity, specificity, positive predictive value and negative predictive values of 99%, 94%, 91%, and 99%, respectively. There was one specimen that was positive by shell vial culture but negative by BD-HSV. All specimens were tested using the LightCycler PCR HSV 1/2 Detection Kit (R-HSV) (Roche Applied Science, Indianapolis, IN) to provide a comparative method to resolve discrepancies. Using a combined standard, a true positive was defined as a positive shell vial culture or a positive by both molecular tests. The recalculated sensitivity, specificity, positive predictive value and negative predictive values using the combined standard were all >99% for BD-HSV and 91%, 100%, 100%, and 95% for the shell vial tissue culture, respectively. The BD- HSV assay on the Viper Instrument proved to be more sensitive than, and as specific as, our shell vial tissue culture method. It also has the added benefit of faster turnaround time, less hands on time, and can be run simultaneously on the Viper Instrument with other assays, e.g. Chlamydia trachomatis and Neisseria gonorrhoeae Antibiograms Arthur E. Crist, Jr., Ph.D. Director, Clinical and Molecular Microbiology Robert M. Patti, PharmD, JD, Manager-Pharmacy Clinical Services Susan Shue, MT (ASCP), Division Manager, Laboratory-Gettysburg Hospital In this month s edition readers are provided with the cumulative 2011 antibiograms for isolates processed by the York Hospital Clinical and Microbiology Laboratory. This year includes inpatient, outpatient, nursing homes and for the first time an antibiogram for isolates recovered in the critical care units. Antibiograms provide an opportunity to ensure appropriate empiric antibiotic coverage when an organism is identified while awaiting susceptibilities. Local patterns of susceptibility and resistance afford comparison to national and regional data when clinicians are developing pathways for the treatment of infections based on established guidelines and recommendations. Antimicrobial susceptibility testing was performed according to the guidelines set forth by the Clinical Laboratory Standards Institute. Antibiotics utilized for development of the antibiograms reflect formulary antibiotics. The only exception is the use of cephalothin testing, which acts as a surrogate for cephalexin (Keflex) testing. Gram negative organisms such as E.coli may be susceptible to cefazolin (Ancef) but at the same time resistant to cephalothin. In this case while cefazolin (Ancef) would be effective therapy, cephalexin (Keflex) would not. Laboratory Services Bulletin [March 2012, Vol. 42. No. 1] 4
5 Organism E. Coli Enterobacter sp. Klebsiella sp. Pseudomonas aeruginosa Staphylococcus aureus (Inpt) (Inpatient Staphylococcus aureus (Outpt) Coagulase neg. Staphylococcus Enterococcus Species H. influenzae Streptococcus pneumoniae Gettysburg Hospital Laboratory Annual Percent Sensitive Antibiogram (2011) Drug Names Amakacin Amoxicillin/Clavulanate Ampicillin Ampicillin/ Sulbactam Azithromycin 50 Cefazolin Cefepime Cefotaxime Ceftriaxone Chloramphenicol Ciprofloxacin Clindamycin Daptomycin Ertapenem Erythromycin Gentamicin Imipenem Levofloxacin Linezolid Nitrourantoin Oxacillin Penicillin Pipercillin/Tazobactam Rifampin Tetracycline Tobramycin Trimeth/Sulfa Vancomycin NOTE: 1. Staphylococcus aureus : Cephalosporins are not effective in vivo for Methicillin Resistant Staph aureus(mrsa) infections. Reporting in vitro results for cephalosporins can be seriously misleading. Vancomycin is currently the drug of choice for MRSA. 2. Staphylococcus epidermidis: Usually regarded as a culture contaminant. However Coag neg Staphylococcus infections are increasing, especially in infections involving foreign devices, surgical wounds, and bacteremia in immunocompromised patients. Cross resistance between methicillin and cephalosporins are substantial. Therefore, all methicillin resistant isolates should be considered resistant to beta-lactam antibiotics. Treatment of choice is either vancomycin alone or in combination with an aminogylcoside or rifampin. 3. Enterococcus: In vitro sensitivity to cephalosporin, clindamycin, and aminoglycosides do not correlate to in vivo results. Therefore the are not reported. Uncomplicated enterococcal infections can be treated with a single therapy of penicillin, ampicillin, or vanocmycin. In serious deep seated infections, a combination therapy of high dose penicillins with an aminoglycoside is recommended. 4. NR= Not reported, insufficient number tested Prepared by: Peggy Waleski MT (ASCP) Laboratory Services Bulletin [March 2012, Vol. 42. No. 1] 5
6 Enterococcus faecalis Enterococcus faecium methicillin susceptible (b) methicillin resistant (b) Staphylococcus sp., coagulase negative Streptococcus pneumoniae Citrobacter freundii complex Enterobacter aerogenes (d) Enterobacter cloacae (d) Escherichia coli Klebsiella pneumoniae Morganella morgani Pseudomonas aeruginosa (c) Serratia marcescens (d) YORK HOSPITAL ANTIMICROBIAL SUSCEPTIBILITY TESTING * ( Jan. - Dec ) Inpatient Isolates Only Prepared by: Arthur E. Crist, Jr., Ph.D., Laboratory Robert Patti, Pharm.D., Pharmacy GRAM (+) COCCI Gram (-) RODS Drug Name Gentamicin (RRF) Tobramycin (RRF) Amikacin (RRF) Penicillin (RRF) Ampicillin (RRF) Amoxicillin/Clavulanate (RRF) Augmentin Ampicillin/Sulbactam (RRF) Unasyn PIP/Tazobactam (RRF) Zosyn Meropenem Ertapenem Imipenem Nafcillin (a) Rifampin (e) Vancomycin (RRF) Gentamicin Synergy Screen (f) Aztreonam Cefazolin (RRF) Cephalothin (g) Cefotetan (RRF) Cefotaxime Ceftriaxone Cefepime (RRF) Azithromycin 51 Clindamycin Doxycycline (h) TMP/SMX (RRF) Daptomycin Linezolid Synercid Nitrofurantoin (i) Ciprofloxacin (RRF) Levofloxacin (RRF) * Antimicrobial susceptibility testing performed according to the guidelines set forth in: (1) Clinical Laboratory Standards Insitute (CLSI). Performance standards for antimicrobial disk susceptibility tests; approved standard-ninth addition. M2-A10, Vol. 29, No. 1. January 2009; (2) CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-seventh edition. M7-A8, Vol. 29, No. 2, January 2009; and (3) CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-First Informational Supplement. M100-S21, Vol. 31, No. 1, January 2011 KEY: (%) Susceptibility is number in block. Dark shaded block = antimicrobic is usually not used or tested for this organism. (a) Oxacillin tested. (b) Fifty five percent (55%) of Staph aureus cultures were methicillin susceptible; 45% were MRSA. (c) For serious pseudomonal infections two antipseudomonal antibiotics should be used. (d) For serious Serratia or Enterobacter infections, cefepime plus an aminoglycoside or a quinolone alone should be used. (e) Should not be used for monotherapy since resistance develops rapidly (f) Predicts synergy when using a beta-lactam and an aminoglycoside in combination therapy (g) Used to predict susceptibility to cephalexin (Keflex) and other first generation cephalosporins (h) Tetracycline tested, a larger percentage of isolates may be sensitive to doxycycline. (i) Urinary tract isolates only (RRF) Means dose should be adjusted for reduced renal function under 50ml/min. If adjustment is needed please contact the Pharmacy. Laboratory Services Bulletin [March 2012, Vol. 42. No. 1] 6
7 Enterococcus faecalis Enterococcus faecium methicillin susceptible (b) methicillin resistant (b) Staphylococcus sp., coagulase negative Streptococcus pneumoniae Citrobacter freundii complex Enterobacter aerogenes (d) Enterobacter cloacae (d) Escherichia coli Klebsiella pneumoniae Morganella morgani Pseudomonas aeruginosa (c) Serratia marcescens (d) YORK HOSPITAL ANTIMICROBIAL SUSCEPTIBILITY TESTING * ( Jan. - Dec ) Outpatient Isolates Only Prepared by: Arthur E. Crist, Jr., Ph.D., Laboratory Robert Patti, Pharm.D., Pharmacy GRAM (+) COCCI Gram (-) RODS Drug Name Gentamicin (RRF) Tobramycin (RRF) Amikacin (RRF) Penicillin (RRF) Ampicillin (RRF) Amoxicillin/Clavulanate (RRF) Augmentin Ampicillin/Sulbactam (RRF) Unasyn PIP/Tazobactam (RRF) Zosyn Meropenem Ertapenem Imipenem Nafcillin (a) Rifampin (e) Vancomycin (RRF) Gentamicin Synergy Screen (f) Aztreonam Cefazolin (RRF) Cephalothin (g) Cefotetan (RRF) Cefotaxime Ceftriaxone Cefepime (RRF) Azithromycin 50 Clindamycin Doxycycline (h) TMP/SMX (RRF) Daptomycin Linezolid Synercid Nitrofurantoin (i) Ciprofloxacin (RRF) Levofloxacin (RRF) * Antimicrobial susceptibility testing performed according to the guidelines set forth in: (1) Clinical Laboratory Standards Insitute (CLSI). Performance standards for antimicrobial disk susceptibility tests; approved standard-ninth addition. M2-A10, Vol. 29, No. 1. January 2009; (2) CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-seventh edition. M7-A8, Vol. 29, No. 2, January 2009; and (3) CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-First Informational Supplement. M100-S21, Vol. 31, No. 1, January 2011 KEY: (%) Susceptibility is number in block. Dark shaded block = antimicrobic is usually not used or tested for this organism. (a) Oxacillin tested. (b) Fifty one percent (51%) of Staph aureus cultures were methicillin susceptible; 49% were MRSA. (c) For serious pseudomonal infections two antipseudomonal antibiotics should be used. (d) For serious Serratia or Enterobacter infections, cefepime plus an aminoglycoside or a quinolone alone should be used. (e) Should not be used for monotherapy since resistance develops rapidly (f) Predicts synergy when using a beta-lactam and an aminoglycoside in combination therapy (g) Used to predict susceptibility to cephalexin (Keflex) and other first generation cephalosporins (h) Tetracycline tested, a larger percentage of isolates may be sensitive to doxycycline. (i) Urinary tract isolates only (RRF) Means dose should be adjusted for reduced renal function under 50ml/min. If adjustment is needed please contact the Pharmacy. Laboratory Services Bulletin [March 2012, Vol. 42. No. 1] 7
8 Enterococcus faecalis Enterococcus faecium methicillin susceptible (b) methicillin resistant (b) Staphylococcus sp., coagulase negative Citrobacter freundii complex Enterobacter cloacae (d) Escherichia coli Klebsiella pneumoniae Morganella morgani Pseudomonas aeruginosa (c) YORK HOSPITAL ANTIMICROBIAL SUSCEPTIBILITY TESTING * ( Jan. - Dec ) Nursing Home Isolates Only Prepared by: Arthur E. Crist, Jr., Ph.D., Laboratory Robert Patti, Pharm.D., Pharmacy GRAM (+) COCCI Gram (-) Rods Drug Name Gentamicin (RRF) Tobramycin (RRF) Amikacin (RRF) Penicillin (RRF) Ampicillin (RRF) Amoxicillin/Clavulanate (RRF) Augmentin Ampicillin/Sulbactam (RRF) Unasyn PIP/Tazobactam (RRF) Zosyn Meropenem Ertapenem Imipenem Nafcillin (a) Rifampin (e) Vancomycin (RRF) Gentamicin Synergy Screen (f) Aztreonam Cefazolin (RRF) Cephalothin (g) Cefotetan (RRF) Cefotaxime Ceftriaxone Cefepime (RRF) Clindamycin Doxycycline (h) TMP/SMX (RRF) Daptomycin Linezolid Synercid Nitrofurantoin (i) Ciprofloxacin (RRF) Levofloxacin (RRF) * Antimicrobial susceptibility testing performed according to the guidelines set forth in: (1) Clinical Laboratory Standards Insitute (CLSI). Performance standards for antimicrobial disk susceptibility tests; approved standard-ninth addition. M2-A10, Vol. 29, No. 1. January 2009; (2) CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-seventh edition. M7-A8, Vol. 29, No. 2, January 2009; and (3) CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-First Informational Supplement. M100-S21, Vol. 31, No. 1, January 2011 KEY: (%) Susceptibility is number in block. Dark shaded block = antimicrobic is usually not used or tested for this organism. (a) Oxacillin tested. (b) Thirty one percent (31%) of Staph aureus cultures were methicillin sensitive; 69% were MRSA. (c) For serious pseudomonal infections two antipseudomonal antibiotics should be used. (d) For serious Serratia or Enterobacter infections, cefepime plus an aminoglycoside or a quinolone alone should be used. (e) Should not be used for monotherapy since resistance develops rapidly (f) Predicts synergy when using a beta-lactam and an aminoglycoside in combination therapy (g) Used to predict susceptibility to cephalexin (Keflex) and other first generation cephalosporins (h) Tetracycline tested, a larger percentage of isolates may be sensitive to doxycycline. (i) Urinary tract isolates only (RRF) Means dose should be adjusted for reduced renal function under 50ml/min. If adjustment is needed please contact the Pharmacy. Laboratory Services Bulletin [March 2012, Vol. 42. No. 1] 8
9 Enterococcus faecalis Enterococcus faecium methicillin susceptible (b) methicillin resistant (b) Staphylococcus sp., coagulase negative Citrobacter freundii complex Enterobacter cloacae (d) Escherichia coli Klebsiella pneumoniae Pseudomonas aeruginosa (c) Serratia marcescens (d) Prepared by: Arthur E. Crist, Jr., Ph.D., Laboratory Robert Patti, Pharm.D., Pharmacy YORK HOSPITAL ANTIMICROBIAL SUSCEPTIBILITY TESTING * ( Jan. - Dec ) Critical Care Isolates Only GRAM (+) COCCI Gram (-) Rods Drug Name Gentamicin (RRF) Tobramycin (RRF) Amikacin (RRF) Penicillin (RRF) Ampicillin (RRF) Amoxicillin/Clavulanate (RRF) Augmentin Ampicillin/Sulbactam (RRF) Unasyn PIP/Tazobactam (RRF) Zosyn Meropenem Ertapenem Imipenem Nafcillin (a) Rifampin (e) Vancomycin (RRF) Gentamicin Synergy Screen (f) Aztreonam Cefazolin (RRF) Cephalothin (g) Cefotetan (RRF) Cefotaxime Ceftriaxone Cefepime (RRF) Clindamycin Doxycycline (h) TMP/SMX (RRF) Daptomycin Linezolid Synercid Nitrofurantoin (i) Ciprofloxacin (RRF) Levofloxacin (RRF) * Antimicrobial susceptibility testing performed according to the guidelines set forth in: (1) Clinical Laboratory Standards Insitute (CLSI). Performance standards for antimicrobial disk susceptibility tests; approved standard-ninth addition. M2-A10, Vol. 29, No. 1. January 2009; (2) CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-seventh edition. M7-A8, Vol. 29, No. 2, January 2009; and (3) CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-First Informational Supplement. M100-S21, Vol. 31, No. 1, January 2011 KEY: (%) Susceptibility is number in block. Dark shaded block = antimicrobic is usually not used or tested for this organism. (a) Oxacillin tested. (b) Fifty six percent (56%) of Staph aureus cultures were methicillin susceptible; 44% were MRSA. (c) For serious pseudomonal infections two antipseudomonal antibiotics should be used. (d) For serious Serratia or Enterobacter infections, cefepime plus an aminoglycoside or a quinolone alone should be used. (e) Should not be used for monotherapy since resistance develops rapidly (f) Predicts synergy when using a beta-lactam and an aminoglycoside in combination therapy (g) Used to predict susceptibility to cephalexin (Keflex) and other first generation cephalosporins (h) Tetracycline tested, a larger percentage of isolates may be sensitive to doxycycline. (i) Urinary tract isolates only (RRF) Means dose should be adjusted for reduced renal function under 50ml/min. If adjustment is needed please contact the Pharmacy. Laboratory Services Bulletin [March 2012, Vol. 42. No. 1] 9
Concise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIX NUMBER 3 November 2014 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Marti Roe SM MLS (ASCP), Sarah Parker MD, Jason Child PharmD, and Samuel R.
More informationBACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)
BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance
More informationAntibiotic Stewardship Program (ASP) CHRISTUS SETX
Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:
More informationAntimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More information2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationINFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER
INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER University of Minnesota Health University of Minnesota Medical Center University of Minnesota Masonic Children s Hospital May 2017 Printed herein are
More informationAberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015
Aberdeen Hospital Antibiotic Susceptibility Patterns For Commonly Isolated s For 2015 Services Laboratory Microbiology Department Aberdeen Hospital Nova Scotia Health Authority 835 East River Road New
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationTable 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.
Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Gram-positive cocci: Staphylococcus aureus: *Resistance to penicillin is almost universal. Resistance
More informationmicrobiology testing services
microbiology testing services You already know Spectra Laboratories for a wide array of dialysis-related testing services. Now get to know us for your microbiology needs. As the leading provider of renal-specific
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationPreserve the Power of Antibiotics
PROVIDERInsight News for providers in Northeast Nebraska April 2016 Preserve the Power of Antibiotics Antimicrobial stewardship interventions have been proven to improve individual patient outcomes, reduce
More information2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More information2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services
2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens
More informationAntimicrobial Susceptibility Patterns
Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXXII NUMBER 6 September 2017 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Stacey Hamilton MT SM (ASCP), Samuel Dominguez MD PhD, Sarah Parker MD, and
More informationRCH antibiotic susceptibility data
RCH antibiotic susceptibility data The following represent RCH antibiotic susceptibility data from 2008. This data is used to inform antibiotic guidelines used at RCH. The data includes all microbiological
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationApproach to pediatric Antibiotics
Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus
More informationC&W Three-Year Cumulative Antibiogram January 2013 December 2015
C&W Three-Year Cumulative Antibiogram January 213 December 215 Division of Microbiology, Virology & Infection Control Department of Pathology & Laboratory Medicine Contents Comments and Limitations...
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More informationQUICK REFERENCE. Pseudomonas aeruginosa. (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.)
Pseudomonas aeruginosa (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.) Description: Greenish gray colonies with some beta-hemolysis around each colony on blood agar (BAP),
More informationLeveraging the Lab and Microbiology Department to Optimize Stewardship
Leveraging the Lab and Microbiology Department to Optimize Stewardship Presented by: Andrew Martinez MLS(ASCP), MT(AMT), MBA Alaska Native Medical Center Microbiology Supervisor Maniilaq Health Center
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationCUMULATIVE ANTIBIOGRAM
BC Children s Hospital and BC Women s Hospital & Health Centre CUMULATIVE ANTIBIOGRAM 2017 Division of Medical Microbiology Department of Pathology and Laboratory Medicine Page 1 of 5 GRAM-POSITIVE BACTERIA
More informationNew Drugs for Bad Bugs- Statewide Antibiogram
New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationAntimicrobial Susceptibility Testing: The Basics
Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories
More informationThe β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How
More informationAntimicrobial susceptibility
Antimicrobial susceptibility PATTERNS Microbiology Department Canterbury ealth Laboratories and Clinical Pharmacology Department Canterbury District ealth Board March 2011 Contents Preface... Page 1 ANTIMICROBIAL
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationAntimicrobial Stewardship/Statewide Antibiogram. Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services
Antimicrobial Stewardship/Statewide Antibiogram Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda CMS and JCAHO
More informationAntibiotic Abyss. Discussion Points. MRSA Treatment Guidelines
Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California
More information2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital
2010 ANTIBIOGRAM University of Alberta Hospital and the Stollery Children s Hospital Medical Microbiology Department of Laboratory Medicine and Pathology Table of Contents Page Introduction..... 2 Antibiogram
More informationPrinciples of Infectious Disease. Dr. Ezra Levy CSUHS PA Program
Principles of Infectious Disease Dr. Ezra Levy CSUHS PA Program I. Microbiology (1) morphology (e.g., cocci, bacilli) (2) growth characteristics (e.g., aerobic vs anaerobic) (3) other qualities (e.g.,
More informationSHC Clinical Pathway: HAP/VAP Flowchart
SHC Clinical Pathway: Hospital-Acquired and Ventilator-Associated Pneumonia SHC Clinical Pathway: HAP/VAP Flowchart v.08-29-2017 Diagnosis Hospitalization (HAP) Pneumonia develops 48 hours following: Endotracheal
More information2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital
2009 ANTIBIOGRAM University of Alberta Hospital and the Stollery Childrens Hospital Division of Medical Microbiology Department of Laboratory Medicine and Pathology 2 Table of Contents Page Introduction.....
More informationOPAT discharge navigator and laboratory monitoring Select OPAT button for ALL patients that discharge on intravenous antimicrobials
Clinical Monitoring of Outpatient Parenteral Antimicrobial Therapy (OPAT) and Selected Oral Antimicrobial Agents Adult Inpatient/Ambulatory Clinical Practice Guideline Appendix A. Coordinating an OPAT
More informationThe Basics: Using CLSI Antimicrobial Susceptibility Testing Standards
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationAppropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases
Appropriate Management of Common Pediatric Infections Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases It s all about the microorganism The common pathogens Viruses
More informationa. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More informationUNDERSTANDING YOUR DATA: THE ANTIBIOGRAM
UNDERSTANDING YOUR DATA: THE ANTIBIOGRAM April Abbott, PhD, D(ABMM) Deaconess Health System Evansville, IN April.Abbott@Deaconess.com Special thanks to Dr. Shelley Miller for UCLA data WHAT WE WILL COVER
More informationHelp with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST
Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to
More informationSolution Title: Antibiotic Stewardship: A Journey Toward the Triple Aim
Solution Title: Antibiotic Stewardship: A Journey Toward the Triple Aim Program/Project Description, including Goals What was the problem to be solved? How was it identified? What baseline data existed?
More informationGeneral Approach to Infectious Diseases
General Approach to Infectious Diseases 2 The pharmacotherapy of infectious diseases is unique. To treat most diseases with drugs, we give drugs that have some desired pharmacologic action at some receptor
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXVII NUMBER 6 July 2012 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine B. Dowell SM, MLS (ASCP); Sarah K. Parker, MD; James K. Todd, MD Each year the Children s Hospital Colorado
More informationSimilar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.
Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Cephalosporins are divided into Generations: -First generation have better activity against gram positive organisms. -Later compounds
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimum Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) Broth dilution: cation-adjusted Mueller-Hinton
More information4 th and 5 th generation cephalosporins. Naderi HR Associate professor of Infectious Diseases
4 th and 5 th generation cephalosporins Naderi HR Associate professor of Infectious Diseases Classification Forth generation: Cefclidine, cefepime (Maxipime),cefluprenam, cefoselis,cefozopran, cefpirome
More informationPerformance Information. Vet use only
Performance Information Vet use only Performance of plates read manually was measured in three sites. Each centre tested Enterobacteriaceae, streptococci, staphylococci and pseudomonas-like organisms.
More informationWhat s new in EUCAST methods?
What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests
More informationCompliance of manufacturers of AST materials and devices with EUCAST guidelines
Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationAntimicrobial Stewardship Program
Antimicrobial Stewardship Program David R. Woodard, MSc, FSHEA, CIC CDC: Antibiotic Resistance Threats in the United States, 2013 http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ CDC Threat Levels
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More information1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient
1 Chapter 79, Self-Assessment Questions 1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient with normal renal function is: A. Trimethoprim-sulfamethoxazole B. Cefuroxime
More informationAntimicrobial Resistance Advisory Workgroup (ARAW) Members
Antimicrobial Resistance Advisory Workgroup (ARAW) Members Jackie Aguilar, BSN, RN Anne Diefendorf, MS, RD Ella Martin, MD Lisa Tibbitts, RN, BSN, MSNed, BC Bobbie Bagley, RN, MS, MCH, CPH Apara Dave,
More informationPrevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase
More informationEducating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges
Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Janet Hindler, MCLS MT(ASCP) UCLA Medical Center jhindler@ucla.edu also working as a consultant with the Association
More informationBactiReg3 Event Notes Module Page(s) 4-9 (TUL) Page 1 of 21
www.wslhpt.org 2601 Agriculture Drive Madison, WI 53718 (800) 462-5261 (608) 265-1111 2015-BactiR Reg3 Shipment Date: September 14, 2015 Questions or comments should be directed to Amanda Weiss at 800-462-5261
More informationAdvanced Practice Education Associates. Antibiotics
Advanced Practice Education Associates Antibiotics Overview Difference between Gram Positive(+), Gram Negative(-) organisms Beta lactam ring, allergies Antimicrobial Spectra of Antibiotic Classes 78 Copyright
More information21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review
(1) Have all important studies/evidence of which you are aware been included in the application? Yes No Please provide brief comments on any relevant studies that have not been included: (2) For each of
More informationTHE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS
THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be
More informationSurveillance for Antimicrobial Resistance and Preparation of an Enhanced Antibiogram at the Local Level. janet hindler
Surveillance for Antimicrobial Resistance and Preparation of an Enhanced Antibiogram at the Local Level janet hindler At the conclusion of this talk, you will be able to Describe CLSI M39-A3 recommendations
More informationUNDERSTANDING THE ANTIBIOGRAM
UNDERSTANDING THE ANTIBIOGRAM April Abbott, PhD, D(ABMM) Deaconess Health System Indiana University School of Medicine - Evansville Evansville, IN April.Abbott@Deaconess.com WHAT WE WILL COVER Describe
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationAntimicrobial Susceptibility Summary 2011
Antimicrobial Susceptibility Summary 2011 Clinical Microbiology Department of Pathology & Laboratory Medicine 45 Antimicrobial Susceptibility Summary Clinical Microbiology Department of Pathology and Laboratory
More informationSMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* ...
SMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* The next-generation MicroScan WalkAway System combines proven technology and reliability with enhanced ease-of-use features to streamline
More informationCanadian Nosocomial Infection Surveillance Program 2018 SURVEILLANCE FOR HEALTHCARE ACQUIRED CEREBROSPINAL FLUID SHUNT ASSOCIATED INFECTIONS
Canadian Nosocomial Infection Surveillance Program 2018 SURVEILLANCE FOR HEALTHCARE ACQUIRED CEREBROSPINAL FLUID SHUNT ASSOCIATED INFECTIONS FINAL November 29, 2017 Working Group: Joanne Langley (Chair),
More informationThe Nuts and Bolts of Antibiograms in Long-Term Care Facilities
The Nuts and Bolts of Antibiograms in Long-Term Care Facilities J. Kristie Johnson, Ph.D., D(ABMM) Professor, Department of Pathology University of Maryland School of Medicine Director, Microbiology Laboratories
More informationRecommendations Regarding Use of Rapid Blood Pathogen Identification Panel Data
Recommendations Regarding Use of Rapid Blood Pathogen Identification Panel Data Trevor Van Schooneveld MD, Scott Bergman, PharmD, BCPS, Paul Fey, PhD, Mark Rupp, MD The Clinical Microbiology laboratory
More informationAntimicrobial Susceptibility Summary 2012
Antimicrobial Susceptibility Summary 2012 Clinical Microbiology Department of Pathology & Laboratory Medicine 46 53 Antimicrobial Susceptibility Summary Clinical Microbiology Department of Pathology and
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationCF WELL Pharmacology: Microbiology & Antibiotics
CF WELL Pharmacology: Microbiology & Antibiotics Bradley E. McCrory, PharmD, BCPS Clinical Pharmacy Specialist Pulmonary Medicine Cincinnati Children s Hospital Medical Center January 26, 2017 Disclosure
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationBad Bugs. Pharmacist Learning Objectives. Antimicrobial Resistance. Patient Case. Pharmacy Technician Learning Objectives 4/8/2016
Pharmacist Learning Objectives Antimicrobial Resistance Julie Giddens Pharm D, BCPS Infectious Disease Clinical Pharmacist OSF Saint Francis Medical Center Peoria, IL The speaker has no conflicts to disclose
More informationADC 2016 Report on Bacterial Resistance in Cultures from SEHOS and General Practitioners in Curaçao
ADC 216 Report on Bacterial Resistance in Cultures from SEHOS and General Practitioners in Curaçao Willemstad, November 217 Authors: Radjin Steingrover clinical microbiologist, head dpt. Microbiology ADC
More informationTABLE OF CONTENTS. Urine - Gram Positive Susceptibility Reporting 1 Staphylococcus species, MRSA...11
Policy #MI\ANTI\v23 Page 1 of 3 Section: Antimicrobial Susceptibility Testing Subject Title: Table of Contents Manual Issued by: LABORATORY MANAGER Original Date: January 10, 2000 Approved by: Laboratory
More informationBacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching Hospital, Bengaluru, India
ISSN: 2319-7706 Volume 4 Number 11 (2015) pp. 731-736 http://www.ijcmas.com Original Research Article Bacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching
More informationEinheit für pädiatrische Infektiologie Antibiotics - what, why, when and how?
Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how? Andrea Duppenthaler andrea.duppenthaler@insel.ch Limping patient local pain swelling tenderness warmth fever acute Osteomyelitis
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimal Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) roth dilution: cation-adjusted Mueller-Hinton
More informationMedicinal Chemistry 561P. 2 st hour Examination. May 6, 2013 NAME: KEY. Good Luck!
Medicinal Chemistry 561P 2 st hour Examination May 6, 2013 NAME: KEY Good Luck! 2 MDCH 561P Exam 2 May 6, 2013 Name: KEY Grade: Fill in your scantron with the best choice for the questions below: 1. Which
More informationAntibiotic Usage Guidelines in Hospital
SUPPLEMENT TO JAPI december VOL. 58 51 Antibiotic Usage Guidelines in Hospital Camilla Rodrigues * Use of surveillance data information of Hospital antibiotic policy guidelines from Hinduja Hospital. The
More informationInfectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles
Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles Conflicts of Interest None at this time May be discussing off-label indications KALIN M. CLIFFORD, PHARM.D., BCPS,
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationChallenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems
Micro 301 Antimicrobial Drugs 11/7/12 Significance of antimicrobial drugs Challenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems Definitions Antibiotic Selective
More informationInteractive session: adapting to antibiogram. Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe
Interactive session: adapting to antibiogram Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe Case 1 63 y old woman Dx: urosepsis? After 2 d: intermediate result: Gram-negative bacilli Empiric antibiotic
More information